Updated:
Lyra Therapeutics, Inc.
Lyra Therapeutics was founded in 2005 and is headquartered in Watertown, Massachusetts.
Lyra Therapeutics, Inc.
Lyra Therapeutics was founded in 2005 and is headquartered in Watertown, Massachusetts. Maria Palasis serves as President and CEO, with the company focused on developing its XTreo platform — a bioresorbable polymer matrix that delivers medication directly to sinus tissue over weeks or months (per public record). The firm concentrates on ENT diseases, particularly chronic rhinosinusitis, which affects roughly 30 million adults in the United States annually. Lyra's lead candidate, LYR-210, is designed for in-office placement during a standard sinus procedure and has completed Phase 2 clinical trials. The company also has a pipeline including LYR-220 for patients who have had prior sinus surgery (per SEC filings, 2023). Lyra went public via a reverse merger in 2019 and raised approximately $75M in its IPO and subsequent follow-on offerings as of early 2023. The company reported around 30 employees in its latest public filing. It maintains a single office in Massachusetts and has not disclosed additional facilities. A structural differentiator is Lyra's proprietary drug-delivery platform, which aims to turn a chronic surgical disease into a medical-managed condition. Rather than developing new drug molecules, Lyra formulates existing corticosteroids into a resorbable implant — a strategy that reduces regulatory risk and capital requirements relative to novel biologics.
General information
Firm type
Asset Manager
Year founded
2005
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Watertown
Corporate office
Watertown, MA, United States
Principals
Maria Palasis
President and Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Lyra Therapeutics?
Maria Palasis has served as President and CEO since 2023, overseeing strategic direction. Clinical and R&D decisions are driven by the executive team and board, which includes venture investors from entities like Domain Associates and Longitude Capital (per SEC filings, 2023).
Is Lyra Therapeutics structured as a family office or an operating company?
Lyra Therapeutics is a publicly traded clinical-stage biotech company, not a family office. It reports to the SEC and files quarterly financials. Its major shareholders are institutional venture capital firms and mutual funds.
What investment stages does Lyra Therapeutics typically target?
Lyra is not an investment firm; it is a drug developer. However, it has raised capital across series A through follow-on public offerings, reflecting a trajectory typical of preclinical-to-commercial-stage biotechs.
What therapeutic areas does Lyra Therapeutics explicitly avoid?
Lyra exclusively focuses on ENT diseases, particularly chronic sinusitis. It has not disclosed activity in oncology, neurology, or other common biotech areas.
How is Lyra Therapeutics related to its parent entities or spinouts?
Lyra Therapeutics has no disclosed parent or subsidiary vehicles. It was formed in 2005 and has operated independently as a single corporate entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: